Comparative effectiveness and safety of adjuvant trastuzumab plus pertuzumab versus trastuzumab emtansine in HER2-positive breast cancer with residual disease after neoadjuvant therapy: a real-world retrospective study - Quiz - MDSpire

Comparative effectiveness and safety of adjuvant trastuzumab plus pertuzumab versus trastuzumab emtansine in HER2-positive breast cancer with residual disease after neoadjuvant therapy: a real-world retrospective study

  • By

  • Zhenghua Liu

  • Xinyu Wang

  • Jiayan Gai

  • Chen Wang

  • Xinlu Yi

  • Yufei Liu

  • Tao Zhou

  • June 26, 2026

  • 0 min

Share

Original Source(s)

Comparative effectiveness and safety of adjuvant trastuzumab plus pertuzumab versus trastuzumab emtansine in HER2-positive breast cancer with residual disease after neoadjuvant therapy: a real-world retrospective study

  • by Zhenghua Liu, Xinyu Wang, Jiayan Gai, Chen Wang, Xinlu Yi, Yufei Liu, Tao Zhou

  • June 26, 2026

Related Content

Integrative oncology in colorectal cancer: evidence-based strategies from prevention through survivorship

A synergistic framework integrating global context and structural features for breast ultrasound lesion detection

Metformin inhibits small intestinal neuroendocrine tumor growth in vivo